Invitrogen Corporation and Biocon Announce Exclusive Agreement to Supply New Source of Insulin to Global Cell Culture Market

Published: Jul 18, 2007

CARLSBAD, Calif. & BANGALORE, India--(BUSINESS WIRE)--Invitrogen Corporation (Nasdaq:IVGN), a provider of essential life science technologies for disease research and drug discovery, has signed an exclusive agreement with Biocon Limited to market pharmaceutical-grade insulin to the global cell culture market. The partnership with Biocon, India’s leading biotechnology firm, will make it easier for pharma and biotech companies to rapidly access this high quality reagent for biological therapeutic manufacturing at a competitive price.

Back to news